Document Detail


Characterization of the behavior of alginate-based microcapsules in vitro and in vivo.
MedLine Citation:
PMID:  19761714     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: Functional formulations providing protection of nutritional products against gastric juice or a capable of delivering them to distinct areas of the gastrointestinal tract are increasingly utilized by the food industry. However, the application of functional excipients that are established in pharmaceutical applications is limited in case of food products, as they are typically not classified as Generally Recognized As Safe (GRAS). MATERIALS: Accordingly, we investigated whether two alginate-based microcapsule preparations (capsule diameter 1 - 2 mm) either based on alginate and maize starch (MS-type) or alginate and casein (OCF27-type) and both created from ingredients classified as food supplements provide functional properties with respect to regional gastrointestinal targeting. METHODS: For this purpose the in vitro disintegration and swelling of the microcapsules was tested in various media. Furthermore, individual microcapsules, magnetically labelled with 100 - 200 microg black iron oxide, were ingested by healthy volunteers under fasting and fed conditions. Gastrointestinal transit as well as the gastrointestinal disintegration behavior were determined by using Magnetic Marker Monitoring. RESULTS: The results of in vitro and in vivo investigations show that both types of microcapsules are resistant to gastric juice for approximately 10 hrs under fasting and fed conditions. However, the disintegration characteristics of the two types of microcapsules within the intestines are different. CONCLUSION: Whilst the MS-type of capsules disintegrated predominantly within the small intestine shortly after gastric emptying, the OCF27-type of capsules underwent a rather slow disintegration predominantly in the colon.
Authors:
M Anschütz; G Garbacz; O Kosch; F Donath; J Wiedmann; W Hoeckh; L Trahms; B Schug; W Weitschies; H Blume
Related Documents :
4835504 - The effect of parietal cell and truncal vagotomy on gastric and duodenal contractile ac...
3420004 - Food intake, gastric secretion, and motility as affected by avian pancreatic polypeptid...
10888574 - Formation of n-(nitrosomethyl)urea in stomachs of experimental pigs and human volunteer...
14535874 - Favourable effect of regular intake of fermented milk containing lactobacillus johnsoni...
6254614 - Increased feeding and hyperglycemia elicited by intracerebroventricular 5-thioglucose.
20510254 - The role of the nop receptor in regulating food intake, meal pattern, and the excitabil...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  International journal of clinical pharmacology and therapeutics     Volume:  47     ISSN:  0946-1965     ISO Abbreviation:  Int J Clin Pharmacol Ther     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-09-18     Completed Date:  2009-10-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9423309     Medline TA:  Int J Clin Pharmacol Ther     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  556-63     Citation Subset:  IM    
Affiliation:
SocraTec R&D, Oberursel, Germany. maria.anschuetz@socratec-pharma.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Alginates / chemistry*
Capsules*
Chemistry, Pharmaceutical
Excipients
Female
Ferrosoferric Oxide / administration & dosage*,  pharmacokinetics*
Gastric Emptying / physiology
Gastrointestinal Transit / physiology
Humans
Hydrogen-Ion Concentration
Male
Sex Characteristics
Solubility
Starch
Stomach / physiology
Young Adult
Chemical
Reg. No./Substance:
0/Alginates; 0/Capsules; 0/Excipients; 1317-61-9/Ferrosoferric Oxide; 9005-25-8/Starch

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Meta-analysis of recent studies on patients admitted to hospital due to adverse drug effects.
Next Document:  Evaluation of the pharmacokinetic interaction between esomeprazole (40 mg) and acetylsalicylic acid ...